The first stage clinical trial for the vaccine was started in Wuhan on March 16 after authorities approved. It has been proceeding smoothly, and its results will be published in April, said Chen Wei, a member of the Chinese Academy of Engineering.
“If the initial results prove the vaccine is safe and produces (desired) effects, we will continue to test its effectiveness overseas through international cooperation if the global epidemic continues to spread,” she said.
In this way, the vaccine may be used in other hard-hit countries as soon as possible to bolster their efforts to control the pandemic, said Chen, also a researcher at the Academy of Military Sciences.
Many countries have shown interest in the candidate vaccine, and Chen said she and her team members are willing to cooperate with their international counterparts in the development of vaccines for the highly infectious disease.
Before putting the vaccine in trials in other countries, domestic trials may include foreigners living in China, she said.
“A vaccine may be the most effective solution to ending the global COVID-19 epidemic,” she said.
It is still unknown when the vaccine will gain approval for use, as it must be proved safe and effective first, Chen said, adding she is confident in its early availability for use.
The first phase clinical trial for the vaccine, conducted in Wuhan, aims to evaluate the safety and tolerance for the vaccine in healthy adults between 18 and 60 years old. A total of 108 volunteers had completed inoculation as of Friday, and are under medical observation.